Elevated Tacrolimus Blood Concentration Due to the Interaction with Nirmatrelvir/Ritonavir During COVID-19 Treatment: A Case Report

Nirmatrelvir/ritonavir, a newly authorized drug for the treatment of COVID-19, is a strong CYP3A4 inhibitor that can interact with many drugs, such as tacrolimus, reducing its metabolism. The reported case is a renal transplant patient who experienced a strong increase in tacrolimus blood concentrat...

Descripción completa

Detalles Bibliográficos
Autores principales: Cordero, Carlos Guzmán, de Vicente, María Sáez-Torres
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10027946/
https://www.ncbi.nlm.nih.gov/pubmed/37037726
http://dx.doi.org/10.1016/j.transproceed.2023.03.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10027946/
https://www.ncbi.nlm.nih.gov/pubmed/37037726
http://dx.doi.org/10.1016/j.transproceed.2023.03.001

Ejemplares similares